

IV to oral switch in children: what is the evidence?


Dr Sanjay Patel, Consultant in Paediatric Infectious Diseases and
Immunology, Southampton Children's Hospital
National clinical advisor for paediatric AMS, NHSE

Contents

- The size of the problem: antibiotic use in children
- Why choose oral antibiotics instead of IVAbs
- How do antibiotics work – PK / PD
- The evidence supporting early IVOS (or exclusive oral therapy) in specific infection phenotypes


We use a lot of IV antibiotics in children (2016-19 data)

A total of 1318 of 1549 episodes (85.1%) with a bacterial phenotype received empiric systemic antibiotics (in the first 2 days of admission). NOTE: recruited children who had blood tests performed




UK HSA point prevalence survey (2023 data)

- 4000 children
- 40% <1 month of age
- >50% tertiary hospitals



30% of general paediatric use for respiratory tract infections

Parenteral use 66% in children (57% in adults)




The use of IVAbs within H@H services

Tower Hamlets H@H service (Jan-Oct 2024)


REFERRALS

■ IVAbs ■ Other




VISITS

■ IVAbs ■ Other



Thanks to Zoe
Tribble

We use a lot of 3rd generation cephalosporins in the UK



The benefits of oral antibiotics

- Economic argument:
 - Reduced length of stay / addressing bed pressures
 - Cost of IVAbs / nursing time administering IVAbs
 - Cost for families of being in hospital
- Patient satisfaction – earlier discharge and ↓cannulation
- Carbon footprint of IVAbs¹
- Patient safety:
 - Adverse drug reactions/ need for genetic testing (aminoglycosides)
- Antimicrobial resistance (AMR)
 - In the individual: narrow versus broad spectrum Ab use


IN THEORY, HOW DO ANTIBIOTICS WORK?



Antibiotics interact with the body – absorption,
distribution, metabolism, and excretion of drugs
(= **pharmacokinetics**)

Antibiotics interact with the bacteria
(= **pharmacodynamics**)

PHARMACODYNAMICS



PHARMACOKINETICS




FIG. 2A Mean plasma levels and standard deviations of cefadroxil after intravenous administration of 2.5 (●), 10 (▽), and 15 mg (▼).




FIG. 2B Mean plasma levels and standard deviations of cefadroxil after oral administration of 2.5 (●), 10 (▽), and 15 mg (▼).

Bioavailability

Also need to consider:

- 1) tolerability in terms of taste and volume of liquid suspensions
- 2) ceiling of dosing for some oral Abs ie excessively high doses increase the chances of side effects such as nausea and diarrhoea



Metronidazole (100%)



Linezolid (100%)



Co-trimoxazole (100%)



Fluconazole (100%)



Rifampicin (100%)



Clindamycin (95%)



Ciprofloxacin (dose adj 100%)



Cephalexin (90%)



**Amoxicillin / flucloxacillin / co-amoxiclav (70%),
azithromycin (60-90%)**

BOTTOM LINE

**THE BACTERIA HAVE NO IDEA
HOW THE DRUG GOT INTO THE BODY!**

A paradigm shift in infection management

- Several seminal large RCTS in adults have challenging / refuted long held beliefs about IVABs:
 - OVIVA: bone and joint infections
 - POET: infective endocarditis (left sided)

1. Li HR et al. Oral versus Intravenous Antibiotics for Bone and Joint Infection. N Engl J Med. 2019 Jan 31;380(5):425-436
2. Iverson K et al. Partial Oral versus Intravenous Antibiotic Treatment of Endocarditis. N Engl J Med. 2019 Jan 31;380(5):415-424

Challenging Dogma in the Treatment of Childhood Infections

Oral Antibiotics and Shorter Durations

Daniel C. Tanti, MPH, BSc (Hons),† Brad Spellberg, MD,‡ and Brendan J. McMullan, BMed, PhD*†*

Pyelonephritis / Gram –ve bacteraemia

- Systematic review (paeds) in infants ≤ 90 days of age:
 - Bacteraemic upper UTI
 - A short IV AB course of ≤ 7 days (after the exclusion of meningitis) versus > 7 days is not associated with 30 day relapse / hospitalisation
 - Non-bacteraemic upper UTI
 - A short IV AB course of ≤ 3 days (after the exclusion of meningitis) versus > 3 days is not associated with 30 day relapse / hospitalisation

Osteoarticular (OA) infections

- Danish study – multicentre
 - children aged 3 months to 17 years presenting with OA infections
 - Exclusion criteria were severe infection (ie, septic shock, the need for acute surgery, or substantial soft tissue involvement), prosthetic material
 - Randomised (1:1) to oral Abs (co-amox if ≤ 5 years, flucloxacillin >5 years) versus IV ceftriaxone
 - Po Abs (123 children) versus IVABs (125 children)

Infective endocarditis

- The Necker experience.....

Neonatal infections (EOS and LOS)

- Dutch / Danish / Exeter experience.....

WHAT ARE THE ABSOLUTE INDICATIONS FOR USING INTRAVENOUS ANTIBIOTICS?



SEVERE SEPSIS (Phoenix)
Time to C max + impact of sepsis on GI absorption



**Failure of enteral absorption
or refusal**



**No oral option due to
resistance**



Conclusions

- Robust data to support early IVOS (or exclusive use of oral Abs) in children with invasive bacterial infections
 - “very few children with invasive bacterial infections benefit from IVAbs over oral antibiotics”
 - **As long as you choose the right oral antibiotic and dose it correctly!**